Latest Regulatory News

A recent expert panel convened by Novitas has strongly endorsed Pacific Edge’s urine-based Cxbladder tests for hematuria evaluation, recommending Medicare coverage based on robust clinical evidence and patient care benefits.

EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.

Clarity Pharmaceuticals reports another metastatic prostate cancer patient achieving undetectable disease markers in its Phase II SECuRE trial, reinforcing promising efficacy and safety of its Cu-SAR-bisPSMA radiopharmaceutical.

Electro Optic Systems reported a 27% revenue drop to $128.5 million in FY2025 but posted a net profit of $18.6 million, boosted by the sale of EM Solutions. The company strengthened its position with key contract wins and acquisitions, including the UK-based Interceptor business and a conditional deal for MARSS.

Greatland Resources posted a robust half-year profit of $342.9 million, driven by full ownership of the Telfer mine and a strong operational ramp-up. The Havieron feasibility study confirms a world-class gold-copper project, setting the stage for future growth.

QMines Limited has significantly upgraded its Develin Creek Mineral Resource, increasing Indicated Resources by 46% and total resources by 14%, setting the stage for Phase 2 development planning.

Regis Healthcare reported a strong 18.4% revenue increase to $667.7 million for H1 2026, despite a 44.8% drop in statutory net profit. The company expanded its aged care portfolio through key acquisitions and declared a fully franked interim dividend.

Minerals 260 has locked in a $220 million strategic funding deal with Franco-Nevada, boosting development and de-risking the Bullabulling Gold Project in Western Australia. This marks Franco-Nevada’s largest Australian investment to date.

Nuix Limited has reported robust half-year results for 1H26, highlighted by a 148% increase in Nuix Neo Annualised Contract Value and a significant boost in profitability and cash flow.

Stanmore Resources delivered record coal production and strong cash flow in 2025 despite softer market prices, declaring a fully franked dividend and guiding a modest production decline for 2026.

Stanmore Resources Limited posted a net loss of US$47.2 million for 2025, impacted by a 21% revenue decline due to lower coal prices despite record production and cost efficiencies. The company declared a fully franked final dividend of US 8.9 cents per share.

Osmond Resources has partnered with Técnicas Reunidas to establish the European Union’s first vertically integrated rare earth production facility, aiming to reduce reliance on imports and boost local supply chains.